Gyre Therapeutics, Inc. (GYRE) Stock

Gyre Therapeutics, Inc. (GYRE) is a Healthcare stock trading at $6.89 (as of 2026-08-21), with a market capitalization of $768.30M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for organ fibrosis, including anti-inflammatory and anti-fibrotic therapies. It markets ETUARY (pirfenidone) for idiopathic pulmonary fibrosis and advances additional candidates in clinical development for conditions such as interstitial lung diseases, hepatitis B–related liver fibrosis, and liver and pulmonary disorders.

Understand Gyre Therapeutics, Inc.: how it makes money

Gyre Therapeutics develops and commercializes small-molecule anti-inflammatory and anti-fibrotic drugs for organ fibrosis, with ETUARY (pirfenidone) already approved for idiopathic pulmonary fibrosis, and additional programs (including F351, hydronidone) advancing through Phase 3 to expand future treatment revenue.

For Gyre, the profit engine is the transition of pipeline assets from Phase 3 into approvals and commercialization, because its operating progress and measurable trial outcomes are centered on clinical studies for fibrosis-related diseases (for both ETUARY and its derivative F351).

Business quality (Weak): The company is better understood through clinical trial operating metrics than through segment reporting, because no clean official revenue segments were provided and the available KPIs are trial enrollment and efficacy and safety measures.

Bull case

  • ETUARY is already approved: ETUARY (Pirfenidone) is approved for idiopathic pulmonary fibrosis, giving the company at least one commercial-stage asset.
  • Phase 3 trial activity and signals: In the Pirfenidone Phase 3 pneumoconiosis trial, 272 patients were enrolled, 52.85% achieved at least one-stage fibrosis regression (Ishak), and serious adverse events were reported at 4.88%.

Bear case

  • Trial outcomes and safety create uncertainty: Even with efficacy signals (52.85% fibrosis regression on Ishak), the Phase 3 program still carries clinical risk, reflected by a nonzero incidence of serious adverse events (4.88%).
  • Current operating profitability appears weak: For the latest reported period (2026-03-31), operating margin was -41.5% and revenue was shown as 0.0B, suggesting limited realized profitability from commercialization in the data provided.
Valuation — source: SEC EDGAR (first-party)
Price$6.89
Market Cap$768.30M
Price / Book5.39
Price / Sales7.34
FCF Yield-0.3%
DCF Value (model)$1.45
DCF Upside vs Price-79.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$116.59M
Net Margin8.5%
Revenue Growth (YoY)10.2%
EPS Growth (YoY)-57.1%
FCF Growth (YoY)-97.0%
Financial Health — source: SEC EDGAR
Altman Z-Score17.77 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($8.48M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPing Zhang
Employees579
CountryUS
IPO Date2006-04-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Esperion Therapeutics, Inc. (ESPR)
  • Neurogene Inc. (NGNE)
  • Nuvectis Pharma, Inc. (NVCT)
  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • Monopar Therapeutics Inc. (MNPR)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • CytomX Therapeutics, Inc. (CTMX)
  • Ironwood Pharmaceuticals, Inc. (IRWD)
GYRE earnings history · GYRE institutional & insider holders · GYRE KPIs & operating metrics · GYRE financials · GYRE investor presentations & press releases · GYRE SEC filings · GYRE peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.